Our top 10 things to watch in the stock market Friday

October payrolls rose 165,000 versus 59,000 expected, unemployment edged down to 4.1% from 4.2%, and the 10-year Treasury yield jumped; market-implied odds of a December Fed rate hike rose to 75%. Nasdaq futures rebounded after the index’s worst day in 19 months, but editors cautioned that it was too early to call the selloff over amid concerns about data-center spending. Company updates were mixed: Airbnb shares rose about 14% after results and guidance beat expectations, while DraftKings fell more than 25% after a revenue shortfall and a cut to its full-year outlook.

Analysis

The key cross-asset signal is a potential regime shift from liquidity-led growth to rates-sensitive earnings: stronger labor data can lift near-term revenue expectations while raising discount rates and the hurdle for long-duration AI and biotech valuations. A rebound in tech after forced selling is not confirmation of a bottom; watch Treasury yields and whether AI infrastructure names stabilize after the next inflation release.

Within AI infrastructure, IREN’s capex restraint alongside reported H100 repricing suggests scarcity can support compute economics, but only if utilization and power availability convert higher pricing into cash returns. If customers delay deployments, contracted pricing will not eliminate financing and buildout risk. Anthropic’s reported valuation ambitions are a sentiment catalyst, not a reliable public-market comparable until IPO terms and demand are observable.

The company-specific setups diverge. DraftKings’ guidance cut raises the possibility that prediction-market investment is consuming capital while competing for users and regulatory bandwidth; the risk extends to Flutter’s FanDuel, though the article provides no evidence that this spending is yet a material earnings drag. Hims & Hers gains a lower-friction route to Lilly products, but Lilly retains product control and may capture more of the economics; verify channel terms and prescription conversion before extrapolating platform growth. Airbnb’s stronger outlook supports travel demand, but higher yields could pressure discretionary bookings. Moderna’s oncology thesis remains clinical and binary; improved near-term results do not establish durable vaccine demand. Elanco’s product momentum is positive, with execution risk if growth relies increasingly on a narrow set of launches.

Key Decisions for Investors

• Avoid treating the Nasdaq bounce as a confirmed washout. Over the next several sessions, monitor the 10-year yield, inflation data, and whether AI-infrastructure selling resumes; a fresh rise in yields alongside failed tech stabilization would argue for keeping duration exposure light.
• For a 1–3 month relative-value expression, consider long ABNB versus short DKNG, sized modestly: Airbnb has a stronger reported outlook while DraftKings cut guidance. Reassess if Airbnb bookings or guidance weaken, or if DraftKings demonstrates improving EBITDA and prediction-market spending produces measurable customer economics.
• Keep IREN on a catalyst watch rather than chasing a sharp rebound. Verify capex, power capacity, customer utilization, and cash-flow conversion in filings and guidance; renewed capex escalation without corresponding contracted revenue would falsify the disciplined-growth case.
• Treat MRNA as event-driven, not a broad biotech recovery trade. Review the investor-day evidence and upcoming oncology data; weak or delayed clinical results would undermine the long-term thesis even if near-term vaccine sales support guidance.
• For HIMS/LLY, track the commercial terms, patient conversion, and product mix of the expanded channel before adding exposure. Lilly could benefit from broader access while limiting the platform’s economics; evidence of stronger HIMS growth without deteriorating unit economics would improve the case.